Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C
Documents
ISIN:
IE000KD0BZ68
NAV (05/10/2026): 45.09 USD All-in-fee (TER): 0.30%
i
Risk Considerations
Investors should note that the Xtrackers ETFs & ETCs are not capital protected or guaranteed and investors in each Xtrackers ETF or ETC should be prepared and able to sustain losses up to the total capital invested. The value of an investment in an Xtrackers ETF or ETC may go down as well as up and past performance does not predict future returns. Investment in Xtrackers ETFs or ETCs involve risks. For a list of related risks please click on the Risks and Terms tab.
Important security note: Warning of attempted fraud in the name of DWS
We have detected that fraudulent individuals are misusing the "DWS" trademark and the names of DWS employees on the internet and social media. These fraudsters are operating fake websites, Facebook pages, WhatsApp groups and Mobile Apps. Please be aware that DWS does not have any Facebook Ambassador profiles or WhatsApp chats. If you receive any unexpected calls, messages, or emails claiming to be from DWS, exercise caution and do not make any payments or disclose personal information. We encourage you to report any suspicious activity to info@dws.com, including any relevant documents and the original fraudulent email. Additionally, if you believe you have been a victim of fraud, please notify your local authorities and take steps to protect yourself.
Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C
Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C
- ISIN: IE000KD0BZ68
IE000KD0BZ68
- Ticker: XGEN LN
XGEN LN
Index key features
The MSCI ACWI IMI GENOMIC INNOV SELCT SCRND 100 aims to reflect the performance of the following market:- Large, medium, and small-capitalisation companies across developed and emerging markets globally
- Securities must meet a certain relevance score threshold with the theme of technological innovation in the genomic healthcare sector to be eligible for inclusion
- Securities issued by entities failing to meet the following ESG standards, amongst others, are excluded: (i) are unrated by MSCI ESG Research; (ii) are assigned an MSCI ESG Rating of CCC; (iii) have any involvement in controversial weapons; (iv) are classified by MSCI in their Business Involvement Screening Research as breaching certain revenue thresholds in controversial activities, including, but not limited to, tobacco, conventional weapons, nuclear weapons, civilian firearms, thermal coal and oil sands extraction; and/or (v) fail to comply with the United Nations Global Compact principles
- Reviewed semi-annually and rebalanced at least quarterly
Documents
A sub fund of Xtrackers (IE) Plc.
- NAV, As of 05/10/2026
- 34.10 GBP
- NAV, As of 05/10/2026
- 45.09 USD
- Total AUM of fund, As of 05/10/2026
- 10.72 M GBP
- All-in-fee (TER)
- 0.30%
- Asset class
- Distribution policy
- Capitalizing
- Sub-fund launch date
- 12/07/2022
Performance
Performance
Discrete
Date | From Sep 2016 to Sep 2017 | From Sep 2017 to Sep 2018 | From Sep 2018 to Sep 2019 | From Sep 2019 to Sep 2020 | From Sep 2020 to Sep 2021 | From Sep 2021 to Sep 2022 | From Sep 2022 to Sep 2023 | From Sep 2023 to Sep 2024 | From Sep 2024 to Sep 2025 | From Sep 2025 to Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total return (USD) | -- | -- | -- | -- | -- | -- | -3.71% | 16.15% | -2.27% | 43.75% |
| Benchmark (USD) | -- | -- | -- | -- | -- | -- | -3.34% | 16.36% | -2.08% | 44.10% |
Source: DWS
Past performance does not predict future returns. Performance shown above is net of fund fees and any index replication costs. ETF performance calculation includes reinvested dividends. Performance figures are reported, based on the values as of the last business day of the relevant reporting month.
Fund portfolio05/10/2026
Fund facts
Fund profile
- ISIN
- IE000KD0BZ68
- Ticker
- XGEN LN
- Sub-fund launch date
- 12/07/2022
- 12/07/2022
- Global certificate
- UCITS compliant
- Fiscal year
- Jan 01 - Dec 31
- USD
- Income treatment
- Capitalizing
- Transparency according to Regulation (EU) 2019/2088
- Article 8
Financial product integrates ESG characteristics (please find further information in the section „Documents“) - Exchange traded fund / Non-exchange traded fund
- Exchange traded fund
Index replication technique
- Investment methodology
- Direct Replication (physically)
- Portfolio structure
- Full Replication
Fund (ETF)
- Fund management company fee
- 0.15%
- Fund fixed fee
- + 0.15%
- Fund all-in fee (TER)
- = 0.30%
The All-in fee comprises the Fixed Fee and the Management Company Fee. The Fixed Fee covers certain administrative expenses including the Administrative Agent Fee, the Custodian Fee, the Registrar, Transfer Agent and Listing Agent Fee and the annual tax in Luxembourg (if any) (the "Taxe d'Abonnement"). Further details are available in the Xtrackers, Xtrackers II and Xtrackers (IE) Plc prospectuses.
Index composition30/06/2026
Index facts
The MSCI ACWI IMI GENOMIC INNOV SELCT SCRND 100 aims to reflect the performance of the following market:
- Large, medium, and small-capitalisation companies across developed and emerging markets globally
- Securities must meet a certain relevance score threshold with the theme of technological innovation in the genomic healthcare sector to be eligible for inclusion
- Securities issued by entities failing to meet the following ESG standards, amongst others, are excluded: (i) are unrated by MSCI ESG Research; (ii) are assigned an MSCI ESG Rating of CCC; (iii) have any involvement in controversial weapons; (iv) are classified by MSCI in their Business Involvement Screening Research as breaching certain revenue thresholds in controversial activities, including, but not limited to, tobacco, conventional weapons, nuclear weapons, civilian firearms, thermal coal and oil sands extraction; and/or (v) fail to comply with the United Nations Global Compact principles
- Reviewed semi-annually and rebalanced at least quarterly
The MSCI Genomic Healthcare Innovation UCITS ETF ARE NOT SPONSORED, ENDORSED, SOLD OR PROMOTED BY MSCI INC. ("MSCI") OR ANY OF ITS AFFILIATES, INFORMATION PROVIDERS OR OTHER THIRD PARTY INVOLVED IN, OR RELATED TO, COMPILING, COMPUTING OR CREATING ANY MSCI INDEX (COLLECTIVELY, THE "MSCI PARTIES"). THE MSCI INDEXES ARE THE EXCLUSIVE PROPERTY OF MSCI. MSCI AND THE MSCI INDEX NAMES ARE SERVICE MARK(S) OF MSCI OR ITS AFFILIATES AND HAVE BEEN LICENSED FOR USE FOR CERTAIN PURPOSES BY PRINCIPAL. NONE OF THE MSCI PARTIES MAKES ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, TO THE ISSUER OR OWNERS OF THESE FUNDS OR ANY OTHER PERSON OR ENTITY REGARDING THE ADVISABILITY OF INVESTING IN FUNDS GENERALLY OR IN THESE FUNDS PARTICULARLY OR THE ABILITY OF ANY MSCI INDEX TO TRACK CORRESPONDING STOCK MARKET PERFORMANCE. MSCI OR ITS AFFILIATES ARE THE LICENSORS OF CERTAIN TRADEMARKS, SERVICE MARKS AND TRADE NAMES AND OF THE MSCI INDEXES WHICH ARE DETERMINED, COMPOSED AND CALCULATED BY MSCI WITHOUT REGARD TO THESE FUNDS OR THE ISSUER OR OWNERS OF THESE FUNDS OR ANY OTHER PERSON OR ENTITY. NONE OF THE MSCI PARTIES HAS ANY OBLIGATION TO TAKE THE NEEDS OF THE ISSUER OR OWNERS OF THESE FUNDS OR ANY OTHER PERSON OR ENTITY INTO CONSIDERATION IN DETERMINING, COMPOSING OR CALCULATING THE MSCI INDEXES. NONE OF THE MSCI PARTIES IS RESPONSIBLE FOR OR HAS PARTICIPATED IN THE DETERMINATION OF THE TIMING OF, PRICES AT, OR QUANTITIES OF THESE FUNDS TO BE ISSUED OR IN THE DETERMINATION OR CALCULATION OF THE EQUATION BY OR THE CONSIDERATION INTO WHICH THESE FUNDS ARE REDEEMABLE. FURTHER, NONE OF THE MSCI PARTIES HAS ANY OBLIGATION OR LIABILITY TO THE ISSUER OR OWNERS OF THESE FUNDS OR ANY OTHER PERSON OR ENTITY IN CONNECTION WITH THE ADMINISTRATION, MARKETING OR OFFERING OF MSCI Genomic Healthcare Innovation UCITS ETF. ALTHOUGH MSCI SHALL OBTAIN INFORMATION FOR INCLUSION IN OR FOR USE IN THE CALCULATION OF THE MSCI INDEXES FROM SOURCES THAT MSCI CONSIDERS RELIABLE, NONE OF THE MSCI PARTIES WARRANTS OR GUARANTEES THE ORIGINALITY, ACCURACY AND/OR THE COMPLETENESS OF ANY MSCI INDEX OR ANY DATA INCLUDED THEREIN. NONE OF THE MSCI PARTIES MAKES ANY WARRANTY, EXPRESS OR IMPLIED, AS TO RESULTS TO BE OBTAINED BY THE ISSUER OF THE FUNDS, OWNERS OF THE FUNDS, OR ANY OTHER PERSON OR ENTITY, FROM THE USE OF ANY MSCI INDEX OR ANY DATA INCLUDED THEREIN. NONE OF THE MSCI PARTIES SHALL HAVE ANY LIABILITY FOR ANY ERRORS, OMISSIONS OR INTERRUPTIONS OF OR IN CONNECTION WITH ANY MSCI INDEX OR ANY DATA INCLUDED THEREIN. FURTHER, NONE OF THE MSCI PARTIES MAKES ANY EXPRESS OR IMPLIED WARRANTIES OF ANY KIND, AND THE MSCI PARTIES HEREBY EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO EACH MSCI INDEX AND ANY DATA INCLUDED THEREIN. WITHOUT LIMITING ANY OF THE FOREGOING, IN NO EVENT SHALL ANY OF THE MSCI PARTIES HAVE ANY LIABILITY FOR ANY DIRECT, INDIRECT, SPECIAL, PUNITIVE, CONSEQUENTIAL OR ANY OTHER DAMAGES (INCLUDING LOST PROFITS) EVEN IF NOTIFIED OF THE POSSIBILITY OF SUCH DAMAGES. No purchaser, seller or holder of this security, product or Funds, or any other person or entity, should use or refer to any MSCI trade name, trademark or service mark to sponsor, endorse, market or promote this security without first contacting MSCI to determine whether MSCI's permission is required. Under no circumstances may any person or entity claim any affiliation with MSCI without the prior written permission of MSCI.
Historical Data
Download historical data in Excel format.
Documents
Product details
Sustainability-related disclosures
Report of income for UK tax purposes
Prospectuses, financial statements and articles of incorporation
Brochures & flyers
Notice to Shareholders
Securities lending documents
MiFID II
Target market[1]
- Type of client
- Retail
Professional
Eligible Counterparty - Knowledge & experience
- Informed
Basic
Advanced - Ability to bear losses
- Investor can tolerate losses (up to the total invested amount)
- Risk indicator (PRIIPS methodology)
- 5
- Client objectives
- Growth
- Minimum time horizon
- Long Term (> 5 years)
- Sustainability preferences
- ESG product applies a dedicated ESG strategy and manufacturer takes into account recognised industry standard
- Minimum proportion invested in environmentally sustainable investments within the meaning of the Taxonomy<PageFootnoteReference component-id='etf-mifid' title="Regulation (EU) 2020/852 of the European Parliament and of the Council of 18 June 2020 on the establishment of a framework to facilitate sustainable investment, and amending Regulation (EU) 2019/2088"></PageFootnoteReference>
- 0.00%
- 1.00%
- Consideration of Principal Adverse Impacts (PAIs)
Costs & charges
- Total ongoing costs of the product
- 0.361% p.a.
- thereof ongoing costs
- 0.300% p.a.
- thereof transaction costs
- 0.061% p.a.
- 0.000% p.a.
As of 20/02/2026
MiFID II
From January 3, 2018, on, investment firms which engage in investment services under the Directive 2014/65/EU (Markets in Financial Instruments Directive – „MiFID II“) have to comply with certain new requirements for the distribution of investment funds under the respective national implementation laws in the individual Member States of the European Union.
As part of the new rules, investment firms are required to identify or review and refine, as the case may be, the target market for each financial instrument they distribute. This means that they have to specify the type(s) of client for whose needs, characteristics and objectives the financial instrument is compatible. Further, MiFID II introduces new cost disclosure requirements which aim at increasing cost transparency for investors on a quantitative as well as on a qualitative level. Accordingly, investment firms have to disclose all relevant costs to the client; i.e. those relevant to the investment service and those relevant to the product. The costs have to be aggregated and provided ex-ante (i.e. before the client purchases a product) as well as ex-post, as the case may be, during the lifetime of the investment on at least a yearly basis.
The asset management companies pertaining to DWS support this process by delivering relevant data to the investment firms to enable them to fulfil their new legal obligations. To provide an enhanced level of transparency, the target market and material product cost related MiFID II data are additionally displayed here below with regard to the relevant investment fund.
Important Notes:
The following data is provided on a voluntary basis only and may as such, without further explanations and additional information, i.e. in particular the information contained in the relevant sales documentation of the investment fund (e.g. fund prospectus, KIID) not be sufficient or suitable to assist a potential investor in taking an informed investment decision. It is therefore recommended that investors also carefully read the sales documentation prior to any potential investment decision, and, in particular in case of any questions, consult their investment advisor.
The information on ongoing product costs may deviate from the cost data contained in the relevant sales documentation of the investment fund (e.g. the KIID). The reason for this is that the requirements to display ongoing costs and charges at product level pursuant to the new MiFID II regulations go beyond the existing disclosure regulations applicable to the asset management companies under their relevant regulatory frameworks (i.e. the UCITS Directive or the AIFM Directive and their respective national implementation laws). For example, the estimated transaction costs of an investment fund are not part of the description of the ongoing costs in the relevant KIID established by the management company. Under MiFID II, an investment firm will however have to disclose such costs as part of the costs of the product in good time prior to a potential investor’s investment decision. Thus, the ongoing costs related to the product displayed here below as “total ongoing costs of the product” may, due to differences in the calculation and disclosure methodology, deviate from the sales documentation of the fund.
DWS does not accept any responsibility or liability whatsoever in relation to the data except in case of gross negligence or wilful misconduct.
Related products
Same asset class
Same region